National Pharmaceutical Pricing Authority (NPPA) fixed the price of 6 formulations under Drugs (Prices Control) Order, 2013 based on the decision of the 91st Authority meeting dated 29.07.2021. The decision was taken against the applications of 7 different marketing companies including Softdeal Pharmaceutical Private Limited, M/s Micro Labs Limited, M/s Pure & Cure Healthcare Pvt. Ltd., M/s Alembic Pharmaceuticals Ltd., M/s Lupin Limited, M/s Zeneka Healthcare Ltd. and M/s Cadila Pharmaceuticals Limited, etc.
According to the NPPA “ORDER S. O. 3162(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the
Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred to as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit, and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4), and (5) thereof;”
DPCO price of Cefixime with Potassium Clavulanate tablet and 5 more!
| Sl. No. | NAME OF THE FORMULATION / BRAND NAME | STRENGTH | UNIT | MANUFACTURER & MARKETING COMPANY | RETAIL PRICE (RS.) |
|---|---|---|---|---|---|
| 1 | Budesonide Respule | Each 2 ml respule contains: Budesonide IP 0.5 mg | Each 2ml Pack | Softdeal Pharmaceutical Private Limited | 17.79 |
| 2 | Paracetamol + Caffeine Tablet | Each uncoated tablet contains: Paracetamol IP 650mg Caffeine IP 50mg | 1 Tablet | M/s Micro Labs Limited | 2.81 |
| 3 | Metoprolol Succinate (ER) + Cilnidipine + Telmisartan Tablet | Each film-coated tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg, (As Extended Release), Cilnidipine IP 10mg Telmisartan IP 40mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Alembic Pharmaceuticals Ltd. | 10.16 |
| 4 | Metoprolol Succinate (ER) + Cilnidipine + Telmisartan Tablet | Each film-coated tablet contains: Metoprolol Succinate IP 47.50 mg eq. to Metoprolol Tartrate 50 mg, (As Extended Release), Cilnidipine IP 10mg Telmisartan IP 40mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Alembic Pharmaceuticals Ltd. | 12.41 |
| 5 | Atorvastatin + Ezetimibe Tablet | Each film-coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg, Ezetimibe IP 10mg | 1 Tablet | M/s Safetab Life Science / M/s Lupin Limited | 33.14 |
| 6 | Cefixime + Potassium Clavulanate tablet | Each film-coated tablet contains: Cefixime Trihydrate IP eq. to Anhydrous Cefixime 200mg, Potassium Clavulanate Diluted IP eq. to Clavulanate Acid 125mg | 1 Tablet | M/s Zeneka Healthcare Ltd. / M/s Cadila Pharmaceuticals Limited | 21.97 |
The NPPA has put some conditions while following the price of formulations that conditions will apply on every individual read the following:
Note:
(a) The manufacturer of the above-mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
Also Read: Wegovy new weight loss drug approved by FDA
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt.
under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
The author has 18 years of experience in the Quality Control, and Quality Assurance departments of Pharmaceutical Manufacturing Companies. Have exposure of all documents for WHO-GMP audits, Export documents, US-FDA documents, Validation of Pharma machinery, and Quality Control Instruments.
Email: darshansinghknl10@gmail.com